• Technegas sales in the US exceed $US1 million (approx. $A1.6 million)
• US installed base reaches 27 systems, up from 17 at end of 2024
• Technegas secures additional VA hospital contract, expanding federal footprint

Cyclopharm Ltd has announced significant milestones for its flagship product Technegas in the United States. Since commencing commercial sales in the US last year, Technegas sales receipts have now exceeded $US1 million (approximately $A1.6 million). This important milestone reflects strong adoption of Technegas by prominent key opinion leaders and institutions across the US, despite current geopolitical uncertainty. Cyclopharm's US installed base has now reached 27 Technegas systems, up from 17 systems at the end of 2024, as momentum continues to build following US FDA approval and targeted market development efforts. Each Technegas installation generates recurring revenue through ongoing consumable usage, creating a sustainable annuity income. The US has now become the fourth-largest revenue-generating market of the 66 countries in which Technegas is used and is expected to become the #1 global market by the end of 2025, demonstrating the product's established clinical value and the significant potential of the US market. Cyclopharm has also secured an additional installation purchase order from another US Department of Veterans Affairs (VA) hospital, further expanding its footprint within the US federal healthcare network. The company's expansion into the US represents a de-risked growth opportunity, supported by Technegas' position as a best-in-class global technology, broad FDA indication, established reimbursement pathways, major US government and private sector contracts, onshore inventory, and long-term local manufacturing plans.

Cyclopharm expects the US to become the #1 global market for Technegas by the end of 2025, demonstrating the significant potential of the US market.